Several clinical publications suggest that anti-CD30 immunotoxic therapy alone, or together with chemotherapy, should benefit from a combination with an ALK inhibitor in patients with chemotherapy-refractory ALK-positive ALCL [20]. This evidence concerns the gene ALK and anaplastic large cell lymphoma.